Ficha del valor · trimestre archivado
HAE
Haemonetics Corporation · Healthcare · Medical - Devices
16Tenedores rastreados
—Δ titulares
7.65MAcciones mantenidas
$633.10MValor declarado
+0Nuevas posiciones
−0Cierres
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q2 2024
Participación a lo largo del tiempo
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 106 | -6 | 39.46M | $2.63B | +3 | −9 |
| Q1 2026 | 115 | +1 | 38.93M | $1.98B | +9 | −9 |
| Q4 2025 | 115 | -1 | 49.79M | $3.32B | +2 | −2 |
| Q3 2025 | 19 | 0 | 21.92M | $1.07B | +1 | −2 |
| Q2 2025 | 17 | +1 | 20.74M | $1.55B | +1 | — |
| Q1 2025 | 13 | -1 | 9.03M | $573.92M | +1 | −2 |
| Q4 2024 | 14 | 0 | 9.30M | $726.05M | +1 | −1 |
| Q3 2024 | 13 | -3 | 7.86M | $631.67M | — | −3 |
| Q2 2024 | 16 | — | 7.65M | $633.10M | — | — |
Quién lo tiene en cartera · Q2 2024
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 3.84M | — | $317.51M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 3.84M | — | $317.51M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 3.84M | — | $317.51M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 3.84M | — | $317.51M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (pasivo) | 1.17M | — | $97.01M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (pasivo) | 1.17M | — | $97.01M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Fisher Asset Management ✦ | 693.05K | — | $57.34M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Norges Bank ✦ (pasivo) | 484.71K | — | $40.10M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 348.06K | — | $28.80M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 348.06K | — | $28.80M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Point72 Asset Management ✦ | 219.02K | — | $18.12M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 201.52K | — | $16.67M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 201.52K | — | $16.67M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 201.52K | — | $16.67M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 140.26K | — | $11.60M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Arrowstreet Capital ✦ | 110.11K | — | $9.11M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 109.70K | — | $9.08M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Millennium Management ✦ | 102.79K | — | $8.50M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 83.99K | — | $6.95M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 83.99K | — | $6.95M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 83.99K | — | $6.95M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Renaissance Technologies ✦ | 55.50K | — | $4.59M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Marshall Wace ✦ | 44.89K | — | $3.71M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Marshall Wace ✦ | 44.89K | — | $3.71M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Bridgewater Associates ✦ | 43.57K | — | $3.60M | 0.0% | n/c | 1 | SEC ↗ |
| 26 | Gotham Asset Management ✦ | 4.92K | — | $406,866 | 0.0% | n/c | 1 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 321 tenedores, 47.04M acciones, $2.56B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Frecuentemente cotituladas
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Procedencia: Participación a partir de posiciones en acciones ordinarias de 13F procesadas (universo rastreado, conjuntos comparables para cambios); filas de iniciados de los Formularios 3/4/5; participaciones de los Schedules 13D/13G; cada filing enlaza con su original en SEC EDGAR.
Período de reporte: Q2 2024 ·
Metodología ·
Obtener esto a través de la API